Clinical trial · Interventional
Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion
Evaluation of Chest Pain, Effectiveness and Safety of Pleurodesis With Pleural Catheters and Silver Nitrate for Malignant Pleural Effusion.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to determinate the degree of chest pain on patients with malignant pleural effusion submitted to pleurodesis with silver nitrate in three different dosages and concentrations ( 30ml 0.5% ; 30ml 0.3% ; 60ml 0.3%). Our secondary purpose is to evaluate the efficacy and occurence of adverse effects in the usage of silver nitrate for pleurodesis in the aforementioned dosages/concentrations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Silver Nitrate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Silver Nitrate 1
- description
- Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
- interventionNames
- Drug: Silver Nitrate
- type
- EXPERIMENTAL
- label
- Silver Nitrate 2
- description
- Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
- interventionNames
- Drug: Silver Nitrate
- type
- EXPERIMENTAL
- label
- Silver Nitrate 3
- description
- Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Malignant pleural effusion confirmed by cytologic analysis of the fluid and/or pleural biopsy. * Recurrent and symptomatic malignant pleural effusion. * Full pulmonary expansion (\>90%) post thoracocentesis, confirmed via chest x-ray. * Karnofsky Performance Status \>30 * Agreement to participate of the study by signing of the Informed Consent Term. Exclusion Criteria: * Coagulopathies (prothrombin activity \<50%) and/or thrombocytopenia (\<80000 count). * Active pleural or systemic infection. * Massive skin neoplastic infiltration. * Inability of understanding the pain scale. * Previous pleural procedures (except for thoracocentesis and/or pleural biopsy). * Refusal to participate of the study.
References
Publications (1)
- BACKGROUNDPaschoalini Mda S, Vargas FS, Marchi E, Pereira JR, Jatene FB, Antonangelo L, Light RW. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest. 2005 Aug;128(2):684-9. doi: 10.1378/chest.128.2.684. PMID 16100154